I feel it is a very positive picture; happy about loading up here for a little ride. Couple of key things mentioned that were not yet noted, new to me since I've not listened to past calls:
-- Don't expect Asonep / Isonep news or early looks at data prior to trial wrap-ups either end 2013 or 1Q 2014 due to trial design
-- Have "signed paperwork" with the DOD already. Will evaluate in different type models.
-- Feel Lpathomab data shows that it has better efficiency than the drug BMY recently ponied up $325M deal for.
-- As a starter, the prospect of a $20M to $40M PFE Opt-In payment in 2Q 2014 should bring the market value to at least twice the current $65M Mkt Cap by that time next year.